– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period –

– New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition –

– Exploratory and Post-hoc CALLIPER Analyses Show Significant Reductions in EBV-Specific T-Cell Receptor Signatures; Observed Reductions Associated With Increased Symbol Digit Modalities Test (SDMT) Scores –

– Post-hoc Analysis of CALLIPER Using a Proposed Novel Disability Measure Suggests Overall Benefit of Vidofludimus Calcium in Progressive Multiple Sclerosis Patients –

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that new clinical, biomarker, and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), are being presented across four poster presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto. All posters are available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Additionally, the team is available throughout the event at booth #516.

"The data presented at MSToronto2026 provide complementary clinical and mechanistic evidence supporting the differentiated profile of vidofludimus calcium across the multiple sclerosis (MS) spectrum," said Erik Lundgren, Chief Executive Officer of Immunic. "Importantly, the new CALLIPER open-label extension (OLE) analyses provide favorable long-term follow-up of the disability signals observed during the double-blind treatment period, while the Nurr1, Epstein-Barr virus (EBV), and disability endpoint analyses provide additional insight into the biology of disease progression and how treatment effects may be more comprehensively measured. Together, these findings further support the clinical and scientific rationale for our planned Phase 3 program in progressive MS, which we expect to initiate later this year, while we also approach the top-line results from our fully enrolled Phase 3 ENSURE trials in relapsing MS, expected by year-end 2026."

New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes

Poster Title: Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

- Lead Author: Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio and Coordinating Investigator of the CALLIPER trial

- Presentation: Paper Poster, Poster Number P0387

- Date and Time: Poster Session 1, Wednesday, October 21, 2026, 4:30 - 6:30 pm ET

New analyses of the Phase 2 CALLIPER trial showed that the favorable trends on disability outcomes observed during the double-blind main treatment period were maintained during the OLE phase among participants who continued vidofludimus calcium treatment. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff, with a safety and tolerability profile that appeared consistent with that observed in the double-blind period.

Preclinical Models Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects

Poster Title: Vidofludimus Calcium Requires Nurr1 to Promote Neuronal Survival In Vitro and Is Associated with Neuroprotective Effects in Murine Models of Multiple Sclerosis

- Lead Author: Mehrnoosh Jafari, Senior Manager Translational Pharmacology at Immunic

- Presentation: Paper Poster, Poster Number P1273

- Date and Time: Poster Session 2, Thursday, October 22, 2026, 4:30-6:30 pm ET

New preclinical findings across multiple models suggest that vidofludimus calcium promotes neuronal survival under apoptotic stress conditions, an effect requiring Nurr1, and in addition reduces microglia-driven neuronal loss, supporting direct and indirect neuroprotective mechanisms. Under in vitro apoptotic conditions, vidofludimus calcium promoted neuronal survival, an effect not observed with teriflunomide, suggesting that the observed pro-survival effect involves mechanisms beyond DHODH inhibition.

Vidofludimus calcium also reduced disease severity and plasma neurofilament light (NfL) chain levels in murine experimental autoimmune encephalomyelitis (EAE) models, and increased brain-derived neurotrophic factor (BDNF) levels and expression of Nurr1-regulated target genes, providing additional evidence consistent with activation of Nurr1-pathways.

Taken together, these findings provide further preclinical evidence of the profile of vidofludimus calcium on pathways associated with neuroprotective effects.

Exploratory and Post-hoc CALLIPER Analyses Link Reduced EBV-Specific T-Cell Signatures with Improved Cognitive Performance as Measured by the Symbol Digit Modalities Test

Poster Title: Anti-EBV T-cell Receptor Repertoire Reduction Is Linked to Enhanced Cognitive Performance in Progressive Multiple Sclerosis: Evidence from the Phase 2 CALLIPER Trial with Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor

- Lead Author: Amelie Schreieck, Ph.D., Senior Manager Biomarker Development at Immunic

- Presentation: ePoster, Number EP2473

- Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

An exploratory CALLIPER analysis found that vidofludimus calcium significantly reduced EBV-specific TCRβ chain (TRB) sequence matches versus placebo-treated patients (-0.65 matches; p=0.0004), while influenza A-specific matches were unchanged (+0.08; p=0.5983), suggesting an EBV-selective rather than generalized effect on the T-cell repertoire, consistent with a lowered rate of EBV reactivations. Across all patients, reductions in EBV-specific TRB matches were associated with improved Symbol Digit Modalities Test (SDMT, broadly used to assess processing speed) scores, as assessed in a post-hoc analysis. Safety and tolerability data from the CALLIPER trial are summarized below.

These exploratory findings support further investigation of the relationship between EBV-related immune activity and cognitive function in progressive MS.

Novel CALLIPER Analyses Evaluate Disability Improvement and Worsening Together

Poster Title: Bidirectional Disability Changes in Progressive Multiple Sclerosis Patients: a Proposed Endpoint to Capture Full Treatment Effects

- Lead Author: James Myles, Global Head of Biostatistics at Immunic

- Presentation: ePoster, Number EP2205

- Date and Time: ePoster screens within the congress center and on the congress platform for the duration of the congress

Traditional progressive MS analyses have focused primarily on delaying confirmed disability worsening, with improvement often not captured fully or assessed separately. This analysis evaluates two novel statistical models, Confirmed Disability Change (CDC) and Generalized Pairwise Comparisons (GPC), as proposed methods to integrate confirmed disability worsening and improvement into a single statistical analysis measure.

Applying both methods to CALLIPER post-hoc, progressive MS patients treated with vidofludimus calcium appeared more likely to have positive outcomes as compared to placebo, suggesting these methods may capture the true bidirectional disability trajectory of patients. The CDC method fits an ordinal logistic regression model to three ordered categories of confirmed disability change. Using data from the CALLIPER trial, patients treated with vidofludimus calcium were 2.47 times more likely to experience 24-week confirmed disability improvement (CDI) (nominal p=0.037), and a positive CDC (nominal p=0.042). The GPC method compares all pairs of patients to determine which patient had a better outcome as measured by improvement, stability, or slowed worsening on the Expanded Disability Status Scale (EDSS) score. By this method, patients on vidofludimus calcium were 1.5 times more likely to have a better outcome than those who received placebo, a statistically significant and clinically meaningful result (p=0.042).

These outcomes support further evaluation of a bidirectional endpoint designed to capture treatment effects across both disability worsening and improvement.

About Vidofludimus Calcium (IMU-838) and the CALLIPER Trial

Vidofludimus calcium (IMU-838) is an investigational oral small molecule activating nuclear receptor-related 1 (Nurr1) and selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). It is currently being evaluated in the Phase 3 ENSURE trials in relapsing multiple sclerosis (MS). More than 3,500 individuals have been exposed to vidofludimus calcium, to date.

The Phase 2 CALLIPER trial randomized 467 patients with primary or secondary progressive MS 1:1 to 45 mg once-daily vidofludimus calcium or placebo. While the primary endpoint of percent brain volume change (PBVC) was not met, exploratory imaging and clinical outcomes showed directionally favorable signals. Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were similar to placebo (69.4% vs. 68.5% and 8.1% vs. 6.5%, respectively), with no new safety signals and no Hy's law range cases observed. Among the 387 participants who entered the OLE phase, 44.4% experienced at least one TEAE, including 5.7% who experienced a serious TEAE. Liver-related TEAEs occurred in 3.1% of participants, and TEAEs leading to discontinuation in 1.8%.

Vidofludimus calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S.

Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain

Findings suggest that TUSC2 may play a foundational role in brain health

AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader understanding of how disruption of normal biological function may contribute to disease.

The study, entitled "Mitochondrial calcium sensor TUSC2 protects the aging hippocampus from proteostasis collapse in a sex-specific manner," was published in Mechanisms of Ageing and Development by researchers at Meharry Medical College. TUSC2 is the therapeutic gene used in Genprex's investigational REQORSA® gene therapy, which is being developed for the treatment of cancer.

The research found that loss of TUSC2 in mice was associated with substantial disruption of mitochondrial function, of protein homeostasis and of pathways involved in neuronal communication within the hippocampus, a region of the brain essential for learning and memory. These effects were markedly more pronounced in male mice than in females, suggesting important sex-specific differences in the biological response to TUSC2 deficiency.

Importantly, the researchers also analyzed existing human gene-expression datasets and found that TUSC2 expression declined significantly with age in 11 of 13 examined brain regions, with additional reductions observed in Alzheimer's disease datasets. Levels of TUSC2 protein in the hippocampus, as in the rest of the brain, decrease as humans age. Comparisons between the mouse findings and human hippocampal aging datasets identified overlapping molecular changes, supporting further investigation of TUSC2's role in brain aging.

While the research did not evaluate REQORSA as a treatment for aging or neurodegenerative disease, the findings expand scientific understanding of the biological functions of TUSC2, the gene underlying Genprex's lead oncology program.

"This research adds to our understanding of the diverse biological functions of TUSC2, the tumor suppressor gene at the center of our REQORSA oncology program," said Mark Berger, Chief Medical Officer of Genprex. "The findings highlight the important role TUSC2 plays in mitochondrial function, cellular stress responses, and protein homeostasis, while revealing intriguing differences between males and females. Importantly, the parallels identified between the preclinical findings and human brain aging data further reinforce the biological significance of TUSC2 beyond its established role in cancer. While these findings are exploratory, they contribute to a growing body of research into the broader functions of this important gene."

The research utilized an engineered mouse TUSC2 knockout (KO) model to investigate how the loss of TUSC2 accelerates molecular changes associated with hippocampal aging, before the onset of overt neurodegeneration. The findings establish the TUSC2 KO model as a valuable tool for investigating early stages of mitochondrial dysfunction, impaired protein homeostasis, and age-related changes in brain function.

Key study highlights:

- Sex-Specific Resilience: The study identified marked differences in mitochondrial stress resilience between male and female mice. While TUSC2 loss in males disrupted mitochondrial, protein homeostasis and synaptic pathways, females exhibited adaptive cellular stress responses, suggesting greater resilience to TUSC2 deficiency.

- Protein Homeostasis: TUSC2 deficiency was associated with impaired protein quality-control pathways and a significant increase in protein aggregate size in the male hippocampus, supporting a role for TUSC2 in maintaining cellular protein homeostasis.

- Synaptic Pathway Maintenance: The researchers identified substantial disruption of pathways involved in neuronal communication and synaptic function including differences between gene expression and corresponding protein levels, suggesting that TUSC2 contributes to the maintenance of normal synaptic processes.

These findings further support the importance of understanding how biological functions are disrupted in aging and how restoring TUSC2 may open new avenues for therapeutic intervention in age-related cognitive disorders.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focusing on developing innovative treatments designed to restore biological functions disrupted by disease. The Company's lead oncology program, REQORSA® Gene Therapy, is being developed for the treatment of lung cancer and is designed to deliver the TUSC2 tumor suppressor gene to help restore tumor-suppressive activity and address multiple pathways involved in cancer progression.

Genprex is also advancing an earlier stage gene therapy program for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors. Across its programs, Genprex is focused on translating innovative gene therapy approaches into meaningful therapeutic advances for patients with significant unmet medical needs.

For more information, please visit https://www.genprex.com/, register for our Email Alerts and follow us on LinkedIn, X, and Facebook.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Contacts:

Genprex, Inc.

(877) 774-GNPX (4679)

GNPX Investor Relations Contact

Lisa DeScenza

[email protected] 

GNPX Media Contact

Kalyn Dabbs

[email protected] 

SOURCE Genprex, Inc.

Share this article

Property ID Introduces NakedHouse.ai, Bringing Property Entitlements Into the Real Estate Transaction

A new report puts expansion and building potential, additional housing, and allowable uses in buyers' and listing agents' hands.

LOS ANGELES, Oct. 21, 2026 /PRNewswire/ -- What can a buyer actually do with a property? The answer often extends well beyond the home described in a listing—and finding it has traditionally required lengthy research, visits to government offices, and a working knowledge of zoning regulations.

Property ID is introducing Entitlements Home Disclosure through NakedHouse.ai to bring that information into the real estate transaction at the time of listing.

The report examines allowable expansion, additional accessory dwelling units, building-height limits, setbacks, and permitted uses. These details can materially affect how buyers evaluate a property, yet they are often missing from the information available when a purchase decision begins.

Among the least understood are the uses a residential property may accommodate beyond a family home. Depending on applicable rules, these may include home-based businesses, family childcare, and other income-producing activities. Qualifying business uses may also carry tax benefits, depending on the activity and the owner's circumstances.

For a buyer, those possibilities can change the calculation: room for an extended family, an additional income source, space to operate a business, or the ability to expand rather than move.

For a listing agent, they provide a fuller account of what is being offered. The existing house is visible. The rights attached to the land often are not.

NakedHouse.ai brings these findings into one report, showing value that the existing home alone may not convey. In some cases, the right to expand, add housing, or accommodate other uses may be worth more than the structure itself, giving agents a compelling basis for presenting the property's full potential.

About Property ID Corporation

Celebrating 50 years in business, Property ID Corporation is a nationally recognized provider of real estate disclosure and property information services, with nationwide coverage. Supported by an extensive natural hazard database and a dedicated in-house research facility, the company combines decades of expertise, advanced technology, and experienced customer support to deliver critical information to real estate professionals and consumers.

"Press Release Service" should be linked to https://www.24-7pressrelease.com/.

SOURCE Property ID Corporation

Share this article

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today the successful completion of the 2026 summer field program at the Upper Kobuk Mineral Projects ("UKMP") in northwestern Alaska's Ambler Mining District, with all priority objectives for the season achieved.

Highlights

- 2026 Field Program Completed with All 42 Planned Geotechnical, Hydrogeological, Condemnation and Exploration Holes Drilled Over Approximately 5,200 Meters

- Target Assessments and Advanced Mapping Completed for District-Wide Exploration Drilling Along 100-Kilometer Volcanogenic Massive Sulfide ("VMS") Belt

- David Thomas Appointed Senior Vice President of Project Development of Ambler Metals to Lead Engineering and Development of the Arctic Project

The UKMP asset portfolio, which encompasses approximately 190,929 hectares and hosts both the high-grade Arctic polymetallic deposit (the "Arctic Project" or "Arctic") and the Bornite copper-cobalt deposit (the "Bornite Project" or "Bornite"), is being advanced by Ambler Metals LLC ("Ambler Metals"). Ambler Metals is a 50/50 joint venture operating company equally owned by Trilogy and South32 Limited (ASX, LSE, JSE: S32; ADR: SOUHY) ("South32"). Arctic is one of the highest-grade, undeveloped open-pittable copper deposits in the world, with an estimated average grade of approximately 5% copper equivalent1,2, bolstered by material precious metals by-product credits.

Tony Giardini, President and CEO of Trilogy, commented: "Delivering the full scope of this season's work safely, with every priority objective met, is a credit to the Ambler Metals team. This summer's program gives our engineers the geotechnical and hydrogeological data they need to finalize Arctic's mine design and infrastructure placement, and it strengthens the technical record supporting our permit applications. We anticipate 2027 being a significant step up in activity: exploration and development drilling at Bornite and along the VMS belt, continued engineering at Arctic, and a Draft Environmental Impact Statement targeted for October 2027. With Dave Thomas now leading project development, the joint venture is positioning Arctic for a potential construction decision following a Record of Decision, targeted for September 2028."

Ambler Metals Concludes 2026 Field Program

Ambler Metals has completed all planned geotechnical, hydrogeological, condemnation and exploration holes for the 2026 season – a total of 42 holes across approximately 5,200 meters of drilling – achieving all priority objectives set for the program. The drill campaign, concentrated at the proposed Arctic mine's waste rock storage facilities and tailings footprint areas, and important groundwater characterization targets, was designed to inform mine design and infrastructure placement and to support the permitting process, while also probing exploration targets along the Arctic mineral horizon.

Regional Exploration: Target Assessments Completed Along the 100-Kilometer VMS Belt

Alongside the Arctic drill program, Ambler Metals completed drill-target assessments of known mineral occurrences and targets across the UKMP mineral belt, achieving another key objective of the 2026 season. The 100-kilometer-long (60-mile-long) VMS belt, which hosts Arctic and numerous other polymetallic mineral deposits and prospects, contains approximately 30 known, historic VMS occurrences and electromagnetic anomalies (see Figure 1). The results of these assessments will be used to rank and prioritize targets, and are expected to underpin planning for accelerated exploration and development drilling in 2027.

Project staff are now focused on preparing for the 2027 field season, including completing equipment maintenance and repairs to support an efficient restart of field operations in April/May 2027.

David Thomas Appointed Senior Vice President of Project Development of Ambler Metals

Ambler Metals has appointed David Thomas as Senior Vice President of Project Development. Mr. Thomas will lead engineering and project development for the Arctic Project, working alongside Ambler Metals President Ron Rimelman as the joint venture advances the project through permitting and toward a construction decision.

Mr. Thomas is a civil engineer with more than 40 years of experience in underground and open-pit mining across North America and internationally, including expertise in Arctic developments. His work spans mine complex design, permitting, project development, start-ups, operations, and closure. He most recently served as Chief Operating Officer of Freedom Copper and, prior to that, as Vice President of Ausenco USA, where he provided engineering oversight for preliminary economic assessments, pre-feasibility studies, and feasibility studies for mining projects in Alaska and across the United States. He has also held senior roles with New Mexico Copper and Sabre Gold, and has been involved in mine permitting in Alaska, Washington, Arizona, Utah, and New Mexico. His Alaska experience includes work at the Red Dog, Fort Knox, Pogo, and Kensington mines during his tenure as President of Alaska Interstate Construction. Internationally, Mr. Thomas served as General Director for Nordgold, working on projects in Siberia and Africa, and as EPCM Manager for Newmont's Hope Bay project in Nunavut, Canada. He holds a Bachelor of Science from the University of Washington.

Ron Rimelman, President of Ambler Metals, commented: "As the Arctic Project advances through permitting, our focus is shifting from defining the project to preparing to build it, and Dave brings the expertise we need at this stage. He has spent four decades designing, permitting, building and operating mines – including Arctic developments and, here in Alaska, operations such as Red Dog, Fort Knox, Pogo and Kensington. His engineering leadership on feasibility-level studies, combined with his hands-on construction and start-up experience, will be invaluable as we translate this season's engineering data into final mine design and lay the groundwork for development. We are delighted to welcome him to the Ambler Metals team."

Qualified Persons

Richard Gosse, P.Geo., Vice President Exploration for Trilogy Metals Inc., is a Qualified Person as defined by National Instrument 43-101 – Standard of Disclosure for Mineral Projects and Subpart 1300 of Regulation S-K. Mr. Gosse has reviewed the technical information in this news release and approves the disclosure contained herein.

About Trilogy Metals

Trilogy Metals Inc. is a metal exploration and development company holding a 50 percent interest in Ambler Metals LLC, which has a 100 percent interest in the Upper Kobuk Mineral Projects ("UKMP") in northwestern Alaska. On December 19, 2019, South32 Limited, a globally diversified mining and metals company, exercised its option to form a 50/50 joint venture with Trilogy Metals. The UKMP is located within the Ambler Mining District which is one of the richest and most-prospective known copper-dominant districts in the world. It hosts polymetallic volcanogenic massive sulfide ("VMS") deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high-grade copper and cobalt mineralization. Exploration efforts have been focused on two deposits in the Ambler Mining District – the Arctic VMS deposit and the Bornite carbonate replacement deposit. Both deposits are located within a land package that spans approximately 190,929 hectares. Ambler Metals has an agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation, that provides a framework for the exploration and potential development of the Ambler Mining District in cooperation with local communities. Trilogy Metals' vision is to develop the Ambler Mining District into a premier North American copper producer while protecting and respecting subsistence livelihoods.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, statements regarding the results of the 2026 field program; expected preparations for, and the timing of, the 2027 field season; expected exploration and development decisions at Bornite and Arctic; expected progress on the permitting process; timing of a draft Environmental Impact Statement and Record of Decision; the anticipated benefits of recent management appointments at Ambler Metals; expectations regarding a construction decision on the Arctic Project; and perceived merit of the properties are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

DELRAY BEACH, Fla., Oct. 21, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the microencapsulation market is projected to grow from USD 16.90 billion in 2026 to USD 24.02 billion in 2031, at a CAGR of 7.3%.

Microencapsulation Market Size & Forecast

- Market Size Available for Years: 2022–2031

- 2026 Market Size: USD 16.90 billion

- 2031 Projected Market Size: USD 24.02 billion

- CAGR (2026–2031): 7.3%

Microencapsulation Market Trends & Insights:

- The microencapsulation market is driven by the growing need to improve the stability, protection, controlled release, and functionality of sensitive ingredients across pharmaceutical, food & beverage, household & personal care, agricultural, textile, and other applications. Rising demand for functional and fortified products, controlled-release formulations, and ingredients with improved shelf stability is driving adoption of microencapsulation technologies. The market also benefits from encapsulation, which protects active ingredients from moisture, oxygen, light, and temperature during processing and storage. Furthermore, advances in encapsulation materials and processing technologies are improving delivery performance, formulation flexibility, and scalability, while ongoing product development across diverse industries is supporting market growth.

- By end-use Industry, the pharmaceuticals segment is estimated to dominate the market with a share of 52.5% in 2026.

- By shell material, polymers are expected to dominate the microencapsulation market.

- By technology, the emulsion technologies segment is expected to witness the fastest growth in the microencapsulation market from 2026 to 2031.

- By core material form, solid accounted for the largest share of 73% of the microencapsulation market in 2026.

- By Core Material, Active Ingredients are projected to account for the largest share of the microencapsulation market during the forecast period.

- Asia Pacific is expected to be the fastest-growing region in the microencapsulation market, registering a CAGR of 8.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438

The microencapsulation market is evolving as manufacturers increasingly use encapsulation technologies to improve ingredient stability, protection, controlled release, and ease of incorporation across food & beverages, pharmaceuticals, household & personal care, agriculture, and other industries. Microencapsulation enables sensitive core materials such as vitamins, minerals, probiotics, flavors, essential oils, bioactive compounds, and active pharmaceutical ingredients to be protected from environmental and processing conditions, including heat, moisture, oxygen, and light. At the same time, manufacturers are expanding encapsulation capabilities across spray, emulsion, coacervation, polymerization, extrusion, and other technologies to address different core materials, shell materials, and release requirements. The growing use of functional and fortified products further encourages incorporating encapsulated ingredients into a broader range of formulations. As demand grows, encapsulation efficiency, ingredient stability, controlled release, process scalability, and compatibility between core and shell materials are becoming increasingly important in the microencapsulation market. Advances in formulation and process design enable manufacturers to better protect and retain sensitive ingredients while producing encapsulated materials suitable for commercial-scale applications.

By core material, the active ingredients segment accounts for the largest share of the microencapsulation market.

The active ingredients segment accounts for a significant share of the microencapsulation market because encapsulation technologies protect sensitive compounds and maintain their stability during processing and storage. Active ingredients can be susceptible to moisture, oxygen, light, temperature, and other environmental conditions that affect their effectiveness. Microencapsulation provides a protective barrier around these materials, improving stability, compatibility, ingredient retention, and controlled release. Growing demand for products requiring enhanced functionality and controlled delivery is further supporting the use of active ingredients as core materials, particularly where protection and release performance are important.

By core material form, liquid is expected to dominate the microencapsulation market.

The dominance of liquid core materials is supported by the extensive use of microencapsulation to encapsulate oils, emulsions, flavors, essential oils, fragrances, and other liquid active compounds within protective shell materials. Encapsulation improves stability by protecting these materials from oxidation, evaporation, moisture, light, and other environmental factors while maintaining their functional properties during processing, storage, and end use. The technology also enables the incorporation of liquid ingredients into solid and liquid formulations while supporting controlled release and improved handling. These benefits make liquid core materials widely utilized across food & beverages, pharmaceuticals, household & personal care, agriculture, and other industrial applications. The broad use of liquid ingredients in commercial formulations, along with microencapsulation's ability to enhance their stability, delivery, and performance, continues to support the liquid segment's leading position in the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=83597438

North America is expected to dominate the microencapsulation market, accounting for the largest share.

North America accounts for a significant share of the microencapsulation market because the food & beverage, pharmaceutical, household & personal care, and agricultural industries extensively use microencapsulation technologies to enhance ingredient stability, functionality, and delivery performance. The region benefits from a well-established manufacturing base, advanced R&D capabilities, and a high concentration of companies involved in specialty ingredients, encapsulation technologies, and formulated products. Microencapsulation is widely used across applications involving flavors, fragrances, vitamins, minerals, bioactive compounds, active ingredients, and agricultural inputs, supporting demand across multiple end-use industries. The widespread adoption of functional foods, nutraceuticals, advanced pharmaceutical formulations, premium personal care products, and controlled-release agricultural products continues to support the use of microencapsulation in the region. In addition, ongoing investments in ingredient innovation, formulation technologies, and value-added products are increasing the use of microencapsulation to improve product stability, shelf life, sensory performance, and controlled-release characteristics. Major market participants, strong technological capabilities, and sustained demand for high-performance products continue to support North America's position in the microencapsulation market.

Top Companies in the Microencapsulation Market

The report profiles key players such as BASF SE (Germany), DSM-Firmenich (Switzerland), International Flavors & Fragrances Inc. (US), Givaudan (Switzerland), Cargill, Incorporated (US), Ingredion (US), Symrise (Germany), DuPont (US), Glanbia PLC (Ireland), Lycored (US), TasteTech (UK), Clextral (France), Vitae Naturals (Spain), Vitablend (Netherlands), and FrieslandCampina (Netherlands), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=83597438

Investment Funding Context

Investment activity in the microencapsulation market is increasingly focused on expanding production capacity and strengthening encapsulation capabilities across food, fragrance, and other applications. In August 2025, DSM-Firmenich announced an investment of approximately EUR 55 million (~USD 64 million) in a 56,000-square-meter greenfield Taste manufacturing plant in Vadodara, Gujarat, India, incorporating encapsulation systems and expected to become operational in Q4 2027. In September 2024, DSM-Firmenich also invested close to S$ 30 million (~USD 23 million) in two new facilities in Singapore, including the Perfumery Automated Compounding Encapsulation (PEACE) Facility. In December 2025, Balchem announced a USD 25 million investment to build a state-of-the-art microencapsulation manufacturing facility in Orange County, New York, expected to open in 2027.

Revenue Shift Context

The global microencapsulation market is shifting toward advanced delivery, protection, and controlled-release solutions across pharmaceuticals, food & beverages, household & personal care, agriculture, textile, and building & construction applications. The market is projected to grow from USD 16.90 billion in 2026 to USD 24.02 billion by 2031, at a CAGR of 7.3%, supported by growing demand for improved ingredient stability, controlled release, taste masking, extended shelf life, and targeted delivery. Pharmaceuticals represent a major demand base, where microencapsulation is used for controlled-release and drug-delivery applications, while adoption is also expanding across food and beverages for protecting sensitive ingredients and improving formulation stability. Growing use in agricultural inputs, personal care formulations, textiles, and construction materials is further broadening the application base, while advances in encapsulation technologies and shell materials support the development of application-specific formulations.

Mergers and Acquisitions

Key players have pursued acquisitions and strategic investments to strengthen their microencapsulation and related ingredient capabilities.

MIAX Launches Physically-settled Fertilizer Futures on MIAX Futures

MIAMI and PRINCETON, N.J., Oct. 21, 2026 /PRNewswire/ -- Miami International Holdings, Inc. (MIAX®) (NYSE: MIAX), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today announced the successful launch of four physically-settled fertilizer futures contracts on MIAX Futures® — NOLA Urea (Ticker: MGU) Futures, NOLA Mono-ammonium Phosphate (Ticker: MAP) Futures, NOLA Di-ammonium Phosphate (Ticker: DAP) Futures, and NOLA Potassium Chloride (Ticker: MOP) Futures.

The four new products are traded on the MIAX Futures Onyx electronic trading platform and cleared through MIAX Futures Clearing.

"Imported fertilizer is a vital input for global food production and with one third of all fertilizer traded by sea passing through the Strait of Hormuz, ongoing volatility in the region exposed significant vulnerabilities in the commodity's supply chain," said Thomas P. Gallagher, Chairman and Chief Executive Officer of MIAX. "MIAX Futures' physically-settled fertilizer futures provide a transparent, exchange-traded mechanism for managing risk and establishing price discovery during times of uncertainty."

"Volatility in global fertilizer markets reinforces the importance of risk-management tools and price transparency throughout the supply chain," said Roger Baker, Vice President, Crop Nutrients Product Line at CHS, a leading global agribusiness and the largest farmer-owned cooperative in the United States. "Customers and suppliers benefit from having access to tools and strategies that can help manage risk as they make purchasing, production and marketing decisions."

"MIAX Futures has worked closely with the agricultural industry for over a century, and we remain committed to supporting the needs of our customers with product and technology innovation," said Shelly Brown, Chief Strategy Officer of MIAX and Chief Executive Officer of MIAX Futures.

For more information, visit https://www.miaxglobal.com/fertilizer-futures-products.

About MIAX

Miami International Holdings, Inc. (NYSE: MIAX) is a technology-driven leader in building and operating regulated financial markets across multiple asset classes and geographies. MIAX® operates eight exchanges across options, futures, equities and international markets including MIAX Options®, MIAX Pearl®, MIAX Emerald®, MIAX Sapphire®, MIAX Pearl Equities™, MIAX Futures®, The Bermuda Stock Exchange (BSX), and The International Stock Exchange (TISE). MIAX also owns Dorman Trading, a full-service Futures Commission Merchant and Notice Registered Broker-Dealer with the National Futures Association for purposes of facilitating transactions of security futures. To learn more about MIAX please visit www.miaxglobal.com. 

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expect," "anticipates," "eventually" or "projected." You are cautioned that such statements are based on management's current expectations and are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Additional risks and uncertainties that may cause actual results to differ materially include the risks and uncertainties listed in MIAX's public filings with the Securities and Exchange Commission. In providing forward-looking statements, the company is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise.

Trading in securities, options, futures, options on futures, or other financial instruments involves risk and is not suitable for all investors. Any trades undertaken will be at the sole risk of the relevant investor and should always be made in compliance with the local laws and applicable regulations. Neither MIAX nor its subsidiaries are registered or licensed to provide, or purport to provide, financial services of any kind in any jurisdiction where MIAX or its subsidiaries are not authorized to do business or where such distribution would be contrary to the local laws and regulations.

All third-party trademarks (including logos and icons) referenced by the company remain the property of their respective owners. Unless specifically identified as such, the company's use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between the owners of these trademarks and the company. Any references by the company to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

MIAX Contacts:

Media

[email protected] 

Investors

[email protected] 

SOURCE MIAX

Share this article

INVE Technologies Announces the Commencement of a $20 Million Modified Dutch Auction Tender Offer for its Common Stock

Announces Preliminary Third Quarter 2026 Financial Results

SANTA ANA, Calif., Oct. 21, 2026 /PRNewswire/ -- INVE Technologies, Inc. (NASDAQ: INVE) ("INVE Technologies" or the "Company") announced today that it has commenced a modified "Dutch auction" self-tender offer to purchase for cash up to $20 million in value of shares of its common stock, $0.001 par value per share, at a price not greater than $3.40 per share nor less than $2.85 per share, net to the seller in cash, less any applicable withholding and, in certain limited circumstances, transfer taxes and without interest. The tender offer commenced today, October 21, 2026, and will expire at 5:00 p.m., New York City time, on Thursday, November 19, 2026, unless extended or terminated. On October 20, 2026, the reported closing price for the common stock on Nasdaq was $2.22 per share. The tender offer is being made as part of the up to $40 million share repurchase program previously authorized by the Company's Board of Directors. The Company also announced preliminary unaudited financial results for the third quarter ended September 30, 2026.

"Following the close of our transaction with Trackonomy, we are delivering on our commitment to return capital to our stockholders," said James Ousley, Chairman of the Board. "We believe this tender offer accelerates that return, while preserving flexibility for future capital returns and strategic acquisitions as we pursue our strategy of acquiring and growing compliance or specialized software businesses that can leverage Physical AI in highly regulated industries."

Modified Dutch Auction Tender Offer

A modified "Dutch auction" self-tender allows stockholders to indicate how many shares and at what price within the range described above (in increments of $0.05 per share) they wish to tender their shares. Based on the number of shares tendered and the prices specified by the tendering stockholders, INVE Technologies will determine the lowest per share price within the range that will enable the Company to purchase $20 million in value of shares, or if a lesser value of shares is properly tendered, all shares that have been properly tendered and not properly withdrawn. INVE Technologies reserves the right, in its sole discretion, to change the per share purchase price range and to increase or decrease the aggregate value of shares sought in the tender offer, subject to applicable law. If shares having an aggregate purchase price of more than $20 million are properly tendered in the tender offer and not properly withdrawn, INVE Technologies reserves the right to accept for purchase pursuant to the tender offer up to an additional 2% of its outstanding shares without extending the expiration time for the tender offer. All shares accepted in the tender offer will be purchased at the same price, even if tendered at a lower price. Any shares tendered may be withdrawn prior to expiration of the tender offer. Stockholders that do not wish to participate in the tender offer do not need to take any action.

If the tender offer is fully subscribed, then shares of common stock having an aggregate purchase price of $20 million will be purchased, representing approximately 24.7 percent to 29.4 percent of INVE Technologies' issued and outstanding shares as of October 19, 2026, depending on the purchase price payable for those shares pursuant to the tender offer.

INVE Technologies will use cash on hand to fund the repurchase of shares in the tender offer and to pay all related fees and expenses. The tender offer is not conditioned upon obtaining financing or any minimum number of shares being tendered; however, the tender offer is subject to a number of other terms and conditions, which are specified in the offer to purchase.

Specific instructions and a complete explanation of the terms and conditions of the tender offer will be contained in the offer to purchase, the related letter of transmittal and the other tender offer materials that will be mailed to registered stockholders shortly and that also can be accessed at the following website: www.dfking.com/INVE. Beneficial holders will receive the offer to purchase and a communication from their bank, broker or custodian.

INVE Technologies' directors and executive officers have advised INVE Technologies that they do not intend to tender their shares in the tender offer.

While INVE Technologies' Board of Directors has approved the making of the tender offer, none of INVE Technologies, its Board of Directors, the dealer manager, the depositary, or the information agent makes any recommendation to any stockholder as to whether to tender or refrain from tendering any shares or as to the price or prices at which stockholders may choose to tender their shares. INVE Technologies has not authorized any person to make any such recommendation. Stockholders must decide whether to tender their shares and, if so, how many shares to tender and at what price or prices. In doing so, stockholders should carefully evaluate all of the information in the offer to purchase, the related letter of transmittal, and the other tender offer materials before making any decision with respect to the tender offer, and should consult their financial and tax advisors.

Craig-Hallum Capital Group LLC is serving as the exclusive dealer manager for the tender offer. The information agent for the tender offer is D.F. King & Co., Inc., and the depositary is Equiniti Trust Company, LLC.

Preliminary Third Quarter 2026 Financial Results

Based on currently available information, INVE Technologies expects to report the following preliminary unaudited results for the third quarter ended September 30, 2026:

Additionally, the Company's cash balance as of September 30, 2026, was $87.1 million. The preliminary financial results set forth above are based on management's initial review of the Company's results for the quarter ended September 30, 2026, and reflect the closing of the asset sale transaction with Trackonomy Systems, Inc. on September 15, 2026. These preliminary financial results are subject to revision based upon the completion of the Company's quarter-end financial closing procedures and the review of its interim financial statements by its independent registered public accounting firm. The Company's independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary results and does not express an opinion or any other form of assurance with respect thereto. Actual results may differ materially from these preliminary estimates, and these estimates should not be viewed as a substitute for full interim financial statements prepared in accordance with U.S. generally accepted accounting principles. The Company expects to report its final complete results for the third quarter of 2026 on or about November 12, 2026.

Certain Information Regarding the Tender Offer

The information in this press release describing the tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell any shares of INVE Technologies, Inc.'s common stock. The tender offer is being made only pursuant to the offer to purchase and the related materials that INVE Technologies is filing with the Securities and Exchange Commission (the "SEC"), and will distribute to stockholders, as they may be amended or supplemented. Stockholders should read the offer to purchase, the related letter of transmittal, and the other tender offer materials carefully and in their entirety because they contain important information, including the terms and conditions of the tender offer. Stockholders of INVE Technologies may obtain a free copy of the Tender Offer Statement on Schedule TO, the offer to purchase, the related letter of transmittal and other tender offer documents that INVE Technologies is filing with the SEC, when available, from the SEC's website at www.sec.gov. Stockholders also will be able to obtain a copy of these documents when available, without charge, from D.F. King & Co., Inc., the information agent for the tender offer, at www.dfking.com/INVE, or by calling D.F. King & Co., Inc. at (800) 515-4507 (toll free). Stockholders are urged to read these materials carefully prior to making any decision with respect to the tender offer. Stockholders who have questions or need assistance may contact the dealer manager for the tender offer, Craig-Hallum Capital Group LLC at (612) 334-6397 or [email protected], or D.F. King & Co., Inc. at [email protected] or the phone number above.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management and can be identified by words such as "anticipate," "believe," "continue," "plan," "will," "intend," "expect," and similar references to the future. Any statement that is not a historical fact, including statements regarding the Company's preliminary estimated financial results for the third quarter ended September 30, 2026; the terms, timing, size and completion of the tender offer, including the value of shares that the Company expects to purchase in the tender offer and whether the Company will actually consummate the tender offer; the Company's beliefs regarding return of capital and creation of stockholder value; and the Company's beliefs regarding its future capital needs, is a forward-looking statement.

MIGDAL HA'EMEK, Israel, Oct. 21, 2026 /PRNewswire/ -- Camtek Ltd. (Nasdaq: CAMT) (TASE: CAMT) announced that it will be releasing its third quarter 2026 results on Wednesday, November 4, 2026.

The Company will host a video conference call later that same day via Zoom, starting at 9:00 am ET. Rafi Amit, Chief Executive Officer, Moshe Eisenberg, Chief Financial Officer and Ramy Langer, President & Chief Operating Officer will host the call and will be available to answer questions after presenting the results and a few opening remarks.

To participate in the Zoom call, please register at the following link:

https://us06web.zoom.us/webinar/register/WN_A25RpmzhT76YdX-pp3Jrwg

Following registration, registrants will be sent the link to the conference call which is accessible either via the Zoom app, or alternatively from a dial-in telephone number. If you have an issue with registration, please contact the Camtek investor relations team, well in advance of the call.

For those unable to participate, the call will be available for replay through the same link, or from a link to the recording on Camtek's website, beginning within a few hours following the end of the call.

ABOUT CAMTEK LTD.

Camtek is a developer and manufacturer of high-end inspection and metrology equipment for the semiconductor industry. Camtek's systems inspect IC and measure IC features on wafers throughout the production process of semiconductor devices, covering the front and mid-end and up to the beginning of assembly (Post Dicing). Camtek's systems inspect wafers for the most demanding semiconductor market segments, including Advanced Interconnect Packaging, Heterogenous Integration, Memory and HBM, CMOS Image Sensors, Compound Semiconductors, MEMS, and RF, serving numerous industries' leading global IDMs, OSATs, and foundries.

With manufacturing facilities in Israel and Germany, and eight offices around the world, Camtek provides state of the art solutions in line with customers' requirements.

This press release is available at www.camtek.com

CAMTEK LTD.

Moshe Eisenberg, CFO

Tel: +972 4 604 8308

Mobile: +972 54 900 7100

[email protected]

INTERNATIONAL INVESTOR RELATIONS

EK Global Investor Relations

Ehud Helft

Tel: (US) 1 212 378 80

[email protected]

SOURCE Camtek Ltd.

Share this article

ECARX Holdings to Report Third Quarter 2026 Financial Results on November 04, 2026

LONDON, Oct. 21, 2026 /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a leading global automotive intelligence company, today announced it will host a conference call and live webcast on Wednesday, November 04, 2026, at 8:00 a.m. ET to report its financial results and business highlights for the third quarter ended September 30, 2026.

Earnings Conference Call & Webcast Details:

Date: Wednesday, November 04, 2026

Time: 8:00 a.m. U.S. ET

Webcast: https://edge.media-server.com/mmc/p/e4i8peb6/lan/en

To join the live conference call, please register at https://register-conf.media-server.com/register/BI9ffd14a76c2a4f01aa0a3d8d55eed7b0 to receive the conference call details as well as international access numbers.

Please join at least 15 minutes in advance to ensure a timely connection to the call and webcast. Audio replay information will be available on ECARX's investor relations website in the news and events section.

A replay of the event and presentation materials will be available on the Company's investor relations website under the results and reports section following the event.

= end =

About ECARX

ECARX (Nasdaq: ECX), headquartered in London, is a leading global automotive intelligence company. ECARX provides the intelligent brain that powers the next generation of software-defined and AI defined vehicles. The company delivers end-to-end, full-stack solutions spanning advanced system-on-chip hardware, high-performance central computing platforms, intelligent cockpit technology, Advanced Driver Assistance Systems, cloud connectivity and physical AI, alongside bespoke vehicle software and intelligent operating systems.

As automakers transition to software-first and AI-first vehicle architectures, ECARX empowers automakers to streamline integration, reduce systemic complexity and optimize long-term cost efficiency. ECARX's proven technology is deployed across over 12 million vehicles worldwide, and is currently partnered with 18 global automakers and 28 vehicle brands to shape the future of automotive intelligence.

Founded in 2017 and listed on Nasdaq in 2022, ECARX operates from 15 major international locations across Europe, the Americas and Asia, with a global team of over 1,400 employees.

Forward-Looking Statements

This release contains statements that are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's beliefs and expectations as well as on assumptions made by and data currently available to management, appear in a number of places throughout this document and include statements regarding, amongst other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. The use of words "expects", "intends", "anticipates", "estimates", "predicts", "believes", "should", "potential", "may", "preliminary", "forecast", "objective", "plan", or "target", and other similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties that could cause actual results to differ materially, including, but not limited to statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, and the markets in which we operate.

For a discussion of these and other risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statement, see ECARX's filings with the U.S. Securities and Exchange Commission. ECARX undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

SOURCE ECARX Holdings Inc.

Share this article

CRITEO TO ANNOUNCE THIRD QUARTER 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO), the global commerce intelligence platform, will announce its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026.

On that day, Michael Komasinski, Chief Executive Officer, and Connor McGogney, Chief Financial Officer, will host a conference call at 8:00 AM ET, 2:00 PM CET to discuss these results.

To access the conference call, please use the following dial-in numbers and ask to be joined into the "Criteo" call:

- United States: +1 800 836 8184

- International: +1 646 357 8785

The conference call will be webcast live on the Company's website https://criteo.investorroom.com/ and will be available for replay.

About Criteo

Criteo (NASDAQ: CRTO) is the global commerce intelligence platform that drives performance for brands, agencies, retailers, and publishers. Built on proprietary commerce data from more than $1 trillion in annual sales and two decades of AI innovation, Criteo helps companies across the ecosystem make smarter decisions and achieve better outcomes, while delivering more relevant experiences for shoppers. With thousands of clients and deep partnerships across global retail and digital commerce, Criteo provides the technology and insights businesses need to compete and grow. For more information, please visit www.criteo.com.

Contacts

Criteo Investor Relations

Melanie Dambre, [email protected]

Criteo Public Relations

Amanda Echavarri, [email protected]

SOURCE Criteo Corp

Share this article